The study of in vitro-in vivo correlation: Pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers

Journal of Pharmaceutical Sciences

Volumn 94, Issue 1, 2005, Pages 220-230

  Srichana, Teerapol ^a   Suedee, Roongnapa ^a   Muanpanarai, Det ^b   Tanmanee, Niwan ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b Phatthalung Hospital   (Thailand)

Author keywords

Aerosol; Albuterol; In vitro in vivo correlation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACTIVATED CARBON; POTASSIUM; SALBUTAMOL;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRY POWDER; EXPIRATORY FLOW RATE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PARTICLE SIZE; POTASSIUM BLOOD LEVEL; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL;

EID: 12244297118     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20218     Document Type: Article

References (17)

1. Jenne JW, Ahrens RC. 1987. Pharmacokinetics of beta-adrenergic compounds. In: Jenne JW, Murphy S, editors. Drug therapy for asthma: Research and clinical practice. New York: Marcel Dekker Inc., pp 213-258.
2. Burgstrom L, Nilsson M. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline. Pharm Res 7:1668-1670.
3. Newman SP. 1983. Deposition and effects of inhalation aerosols. Lund: Astra Draco, pp 95-101.
4. Hindle M, Chrystyn H. 1994. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax 49:549-553.
5. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. 1997. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J 10:2484-2489.
6. Lipworth BJ, Clark DJ. 1997. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 52:1036-1039.
7. Whyte KF, Addis GJ, Whitesmith R, Reid JL. 1987. The mechanism of salbutamol-induced hypokalemia. Br J Clin Pharmacol 23:65-71.
8. British Pharmacopoeia. 1998. Volume I & II. London: The Stationery Office, Appendix XXVII, pp A193-A196.
9. Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 58:125-129.
10. The United States Pharmacopeia 24. 2000. Physical tests and determination [601] aerosols, metered dose inhalers and dry powder inhalers. Rockville, MD: United States Pharmacopeial Convention, Inc., p 1895.
11. Srichana T, Martin GP, Marriott C. 1998. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm 167:13-23.
12. ICH. 1996. Good clinical practice guidelines. Ontario: Minister of Health, Therapeutic Directorate, Health Canada.
13. American Thoracic Society. 1987. Standards for the diagnosis and care of patients with chronic obstructive pulmonary diseases and asthma. Am Rev Respir Dis 136:225-243.
14. Schmeer K, Sauter T, Schmid J. 1997. Rapid pharmacokinetic screening of salbutamol in plasma samples by column-switching high-performance liquid chromatography-electrospray mass spectrometry. J Chromatogr A 777:67-72.
15. Needham SR, Brown PR. 2000. The high performance liquid chromatography electrospray ionization mass spectrometry analysis of diverse basic pharmaceuticals on cyanopropyl and pentafluorophenylpropyl stationary phases. J Pharm Biomed Anal 23:597-605.
16. CPMP/EWP/4151/00. 2004. The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicines for Human Use. London: Author.
17. Gumbhir-Shah K, Kellerman DJ, De Graw S, Koch P, Jusko WJ. 1999. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 12:353-362.